万古霉素粉末在初次及翻修髋膝关节置换术后降低感染的效果及其并发症:一项伞状综述与Meta分析
该伞状综述与Meta分析纳入10项二次研究(含22项原始研究、共137,651例患者),评估术中万古霉素粉末(VP)在初次或翻修髋膝关节置换中预防假体周围感染(PJI)的疗效与安全性。汇总数据显示VP未显著降低总感染(RR 0.86,95%CI 0.62–1.18)、浅表感染或PJI,高质量随机及前瞻性研究同样未显示预防获益,回顾性研究提示获益但证据确定性低至极低。VP未增加局部伤口并发症或全身不良事件。
要点
- 汇总分析显示万古霉素粉末未显著降低总感染(RR 0.86,95%CI 0.62–1.18)。
- 高质量随机及前瞻性研究未显示万古霉素粉末的预防获益,回顾性研究证据确定性低至极低。
- 万古霉素粉末未增加局部伤口并发症或全身不良事件。
核心结论
- 来自随机及前瞻性研究的稳健证据不支持在髋或膝关节置换中常规使用万古霉素粉末预防感染。
- 回顾性分析中的有利结果不足以抵消高质量试验中缺乏获益的证据。
- 在出现更强证据之前,不能推荐常规术中应用万古霉素粉末。
研究设计与样本
- 系统检索PubMed、Scopus、Cochrane CENTRAL、Web of Science、Embase及CINAHL,纳入1990年1月至2024年1月发表的研究。
- 纳入比较术中抗生素粉末与无粉末的初次或翻修关节置换试验,合并风险比(RR)及95%置信区间(CI)。
- 共纳入10项二次研究(含22项原始研究、137,651例患者),均评估万古霉素粉末。
- 采用AMSTAR 2、ROB 2及ROBINS-I评估方法学质量,采用GRADE评级证据确定性。
- 分层分析考察剂量、手术类型及给药技术。
主要发现
- 汇总数据显示万古霉素粉末未显著降低总感染(RR 0.86,95%CI 0.62–1.18)。
- 万古霉素粉末未显著降低浅表感染或PJI。
- 高质量、随机及前瞻性研究同样未显示预防获益。
- 回顾性研究提示获益,但其证据确定性为低至非常低。
- 应用万古霉素粉末未增加局部伤口并发症或全身不良事件。
关键数值与推荐
- 总感染:万古霉素粉末组 vs 无粉末组 RR 0.86(95%CI 0.62–1.18),未达统计学显著。
- 浅表感染及PJI:万古霉素粉末未显著降低。
- 局部伤口并发症及全身不良事件:万古霉素粉末未增加。
临床怎么用
- 作者结论指出,来自随机及前瞻性研究的稳健证据不支持在髋或膝关节置换中常规使用万古霉素粉末预防感染。
- 作者结论指出,在出现更强证据之前,不能推荐常规术中应用万古霉素粉末。
局限性
- 回顾性研究提示万古霉素粉末获益,但其证据确定性为低至非常低。
- 在出现更强证据之前,不能推荐常规术中应用万古霉素粉末。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Periprosthetic joint infection (PJI) after hip or knee arthroplasty greatly increases morbidity and costs. Local antibiotic powders may help curb infections while minimizing systemic toxicity. We assessed their efficacy and safety in preventing PJI. METHODS: We systematically searched PubMed, Scopus, Cochrane Central Registry of Clinical Trials (CENTRAL), Web of Science, Embase, and Cumulative Index to Nursing and Allied Health Literature for studies published from January 1990 to January 2024. Eligible trials compared intraoperative antibiotic powder with no powder in primary or revision arthroplasty. Risk ratios (RRs) with 95% confidence intervals (CIs) were pooled. Methodologic quality was assessed using A MeaSurement Tool to Assess systematic Reviews (AMSTAR 2), ROB 2, and ROBINS-I; evidence certainty was rated with Grading of Recommendations Assessment, Development, and Evaluation (GRADE). Stratified analyses examined dose, surgical type, and administration technique. There were 10 secondary studies (comprising 22 primary studies with 137,651 patients)-all evaluating vancomycin powder (VP)-that met the inclusion criteria. RESULTS: Pooled data showed no significant reduction with VP in total infections (RR 0.86, 95% CI, 0.62 to 1.18), superficial infections, or PJI specifically. High-quality, randomized, and prospective studies have likewise demonstrated no prophylactic benefit. Retrospective studies suggested benefit, but their certainty was low to very low. The application of VP did not increase local wound complications or systemic adverse events. CONCLUSIONS: Robust evidence from randomized and prospective research does not support the routine use of vancomycin powder to prevent infection in hip or knee arthroplasty. Favorable findings from retrospective analyses are insufficient to outweigh the lack of benefit in high-quality trials. Routine intraoperative VP application cannot be recommended until stronger evidence emerges.
引用
- Salimi M, Keshtkar A, Abdelnaser MK, et al. Effect of Vancomycin Powder in Reducing Infection After Primary and Revision Hip and Knee Arthroplasty and Its Complications: An Umbrella Review and Meta-Analysis. J Arthroplasty. 2025. PMID: 41161512. doi:10.1016/j.arth.2025.10.053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。